Related Experiment Videos

Pentoxifylline attenuates pulmonary macromolecular leakage after intestinal ischemia-reperfusion

M B Carter1, M A Wilson, W B Wead

  • 1Department of Surgery, School of Medicine, University of Louisville, Ky, USA.

Abstract

Insights

Pentoxifylline treatment post-intestinal ischemia-reperfusion attenuated pulmonary injury and improved cardiac output in rats. This suggests pentoxifylline may be a potential therapy for acute pulmonary dysfunction.

Area of Science:

  • Physiology
  • Pharmacology
  • Pulmonary Medicine

Background:

  • Intestinal ischemia-reperfusion (I-R) can lead to systemic complications, including acute pulmonary injury.
  • Assessing the efficacy of therapeutic interventions in mitigating these complications is crucial.

Purpose of the Study:

  • To evaluate the effects of pentoxifylline on hemodynamic variables and pulmonary injury following intestinal I-R in a rat model.
  • To utilize advanced fluorescent intravital pulmonary videomicroscopy for precise outcome measurement.

Main Methods:

  • Male Sprague-Dawley rats underwent intestinal I-R, with hemodynamic parameters and arterial blood gases monitored.
  • Pulmonary videomicroscopy quantified alveolar albumin leakage, serving as the primary outcome measure.
  • Pentoxifylline was administered post-ischemia, and data were collected before, during, and after reperfusion.

Main Results:

  • Intestinal I-R significantly increased alveolar macromolecular leakage and caused hemodynamic instability, including decreased blood pressure and cardiac output.
  • Pentoxifylline treatment attenuated pulmonary leakage and mitigated the reduction in cardiac output.
  • No significant effects of pentoxifylline were observed on mean arterial blood pressure, heart rate, or metabolic acidosis.

Conclusions:

  • Pentoxifylline administration after intestinal ischemia reduces alveolar capillary membrane injury and protein leakage.
  • The drug also demonstrates a beneficial effect on cardiac output in this model.
  • These findings support pentoxifylline as a potential therapeutic agent for acute pulmonary dysfunction, warranting further clinical investigation.

Related Concept Videos